Kairos Pharma, Ltd. · AMEX:KAPA
Kairos Pharma — Investor Presentation (September 2026)
25 slides from Kairos Pharma's investor presentation, Sep 14, 2026
Slide 1: Investor Presentation
KAIROS J \— PHARMA INVESTOR PRESENTATION NYSE American: KAPA kairospharma.com
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS KAIROS PHARMA This presentation may contain “forward-looking statements” regarding the current expectations and projections about future events of Kairos Pharma, Ltd. ("Kairos Pharma” or the “Company”). "Forward-looking statements” (statements as to matters other than hist
Slide 3: Our Mission
OUR MISSION Kairos Pharma is dedicated to advancing therapies to overcome critical challenges in cancer drug resistance and immune suppression.
Slide 4: Kairos Highlights
K | KAIROS HIGHLIGHTS / kalros ; : Kw PHARMA Problem: Resistance develops for even blockbuster drugs like anti-androgen therapies (prostate cancer), Tagrisso (NSCLC) Solution: CD105 elevated with resistance. Our antibody ENV 105 reverses resistance . IN NOVATIVE Big opportunities - resistance in pro
Slide 5: Portfolio of Innovative Drugs
PORTFOLIO OF INNOVATIVE DRUGS a a a a CANDIDATE MOA studies CLINICAL TRIALS: CLINICAL TRIALS: CLINICAL TRIALS US Market Antibody targeting CD105 to rs KAIROS PHARMA Antibody targeting CD105 EGFR-driven 2B to reverse resistance to $ EGFR targeted drugs lung cancer Activated % ‘Small molecule function
Slide 6: Mechanisms of resistance to cancer therapies
Mechanisms of resistance to cancer therapies KAIROS | TKI Resistance Radiotherapy Immune Therapy Hormone Therapy Resistance Resistance Resistance GRP SF Qik vad e Secondary Mutations e Evasion of Apoptosis e PD-L1 Upregulation © AR Splice Variants e Bypass Signaling e Enhanced DNA repair ¢ T Cell Ex
Slide 7: ENV105 supporting EGFR-driven lung cancer patients
ENV105 2. SUPPORTING EGFR-DRIVEN LUNG CANCER PATIENTS - In Phase I eo Pe Prostate Lung jw Cancer Overall survival am eda Lung = Log rank test P = 0.0265 Cancer 2 é — Low CD105 exp. Anti-androgen a EGFR drugs a = High CD105 exp] (enzalutamide, (osimertinib, Ss 44 abiraterone, apalutamide) erlotinib,
Slide 8: ENV105 in EGFR-Driven Lung Cancer
ENV105 in EGFR-Driven Lung Cancer AstraZeneca’s EGFR inhibitor Tagrisso ($7B in 2024 sales) offers only a partial response in 80% of patients CD105 is elevated with Tagrisso treatment Preclinical models show ENV105 can overcome resistance and shrink tumors ENV105 could not only reverse resistance bu
Slide 9: ENV105 in Lung Cancer: NCT05401110
ENV105 INLUNG CANCER: NCT05401110 PEP. PHASE 1 TRIAL FOR EGFR-DRIVEN LUNG CANCER: Osimertinib (Tagrisso) + ENV105 : a Patients that have become Lung resistant to Tagrisso Cancer N=9-20 Patients that are incompletely Ale Safety lead-in treated with Tagrisso C) Bayesian design N=20 (persistent ctDNA)
Slide 10: ENV105 restores sensitivity to hormone therapy
ENV105 restores sensitivity to hormone therapy Targets CD105-mediated PROSTATE CANCER castrate resistance Dd ENV105 kills cancer cells resistant to AR Tx (H&E stain in PDX model) More differentiated smaller tumor: 5° eh ENV105 inhibits the creation of the AR splice variant which has resistance to AR
Slide 11: ENV105 in Prostate Cancer
ENV105 F IN PROSTATE CANCER Didd PRESENT RANDOMIZED PHASE 2 TRIAL: NCT03418324 Apalutamide with or without ENV105 lupron extend treatment with combination therapy @-@ apalutamide single agent for compassionate use enzalutamide abiraterone en en oe oe ie @-@ apalutamide + ENV105 Prostate N=10 Cancer
Slide 12: Phase Patient Summary NCT05534646
Phase 2 Patient Summary NCT05534646 Did Apalutamide and ENV105 for the Treatment of Metastatic Castration-Resistant Prostate Cancer Patient Age at RECIST/PWCG 1D enrollment Previews therapies @ week 16 001 88 759 Abiraterone Stable disease 002 16 278.55 Enzalutamide, Lu-PSMA Not assessable (unrelate
Slide 13: Radiographic PFS points of reference
Radiographic PFS points of reference CARD Trial ARPI-switch median PFS = 3.7 months Cabaxitaxel median PFS = 8 months N=255 100 Cabazitaxel 30 | Androgen- signaling— targeted — Percentage of Patients Progression-free Surv No. at Risk Cabazitaxel ‘Androgen-signaling— targeted inhibitor inhibitor soy
Slide 14: Progression Free Survival NCT05534646
Progression Free Survival NCT05534646 ni 1) a b> 2) EE > 3) ED __ a D> sa coi 5) D> G)nrelated withdrawal ed Median PFS = 15.85 months” | aD 8 | =>» * Patients continue to be evaluated a 1@) Ss c~w =)
Slide 15: Change in PSA
Change in PSA NCT05534646 20 < -10 ny a & oO 2 s ~-40 gs z A -70 -100 Comparing baseline pre- treatment PSA to nadir PSA values 35% mean PSA decrease —
Slide 16: Radiation Therapy Resistance
Radiation Therapy Resistance 1. Enhanced DNA Damage ENV105 Repair PARP inhibitors (carotuximab) Radiation . Therapy 1. Tumor Hypoxia HIF activated drugs 705) endoglin BMP4 a cance S ia aed d Notch lockin g Wnt, Hedgehog, and Note: i r ) TRRII ALKS 4 _ BMPRII ALK1 1/ Cell Survival Pathways | EGFR, P1
Slide 17: Carotuximab (ENV105) and Radium-223 (Xofigo) combination study
Efficacy and Safety Study of carotuximab (ENV105) and Radium- K Xx 223 (Xofigo) combination in a bone metastatic mouse model Preclinical collaboration Combining Xofigo with ENV-105 in animal models of bone metastatic prostate cancer Supporting a Phase 2 Clinical Trial Xofigo/ENV-105 combination in b
Slide 18: Overcoming Immune Therapy Resistance
Overcoming Immune Therapy Resistance GITR agonist promote cytotoxic T cell expansion and down regulation of immunosuppressive T cells wit, © Fae se 18 Tregs E CD8:Treg ee 10- = KROS-101 0 0 or r 1 PBS —_ KROS-101 PBS KROS-101 PBS —_ KROS-101 Pes = KROS-101 — |
Slide 19: Clinical Trials
Clinical Trials KAIROS PHARMA Cedars-Sinai Medical Center Maya ties CRO consortium Stanford leveraging the the Centralized regulatory efficiencies of each oversight and institutional Vanderbilt institute to achieve 40 day investigator-initiated trials clinical trial activation are subsidized Rutgers
Slide 20: Current Non-dilutive Funding
Current Non-dilutive funding $3.2M (NCI) ENV105 prostate cancer a companion biomarker validation $2.4M (Donor) ENV105 lung cancer preclinical and phase 1 trial $1.8M (DOD) ENV105 lung cancer companion biomarker identification $2.5M (Donor) KROS201 glioblastoma Phase 1 trial $0.6M (DOD) ENV205 cachex
Slide 21: Strong Intellectual Property
STRONG INTELLECTUAL PROPERTY KAIROS UNDATION PHARMA IP extends to 2040 ©OO©® Published patents Exclusive, worldwide rights to IP executed internationally licensed from Cedars Sinai Medical Center Key IP generated from Murali, Bhowmick and Yu labs KROS101 KROS201 KROS301 KROS401 ENV105 PCT/US2019/045
Slide 22: Leading Team
LEADING TEAM RBS PHARMA Ramchandran Murali, Ph.D John S. Yu, MD VP, RESEARCH AND DEVELOPMENT ceo ce Professor, Biomedical Sciences and Research in Immunology Professor of Neurosurgery, Director Surgical Neuro- at Penn/Cedars-Sinai Medical Center. Oncology at Cedars-Sinai Medical Center ‘+ BAS from S
Slide 23: Independent Directors
INDEPENDENT DIRECTORS Rahul Singhvi, Sc.D. Chemical engineering from MIT. MBA from the Wharton School of the University of Pennsylvania, where he graduated as a Palmer Scholar. : Global leader in the Life Sciences industry and is cofounder of the biomanufacturing company, Resilience (National Resili
Slide 24: Kairos Pharma Summary
Kairos Pharma SUMMARY KAIROS PHARMA ¢ Clinical stage company with an antibody that impacts a central mechanism of CANCER DRUG RESISTANCE e Pipeline targets IMMUNE SUPPRESSION e Enrolling in phase 1 and 2 trials with interim efficacy data in 2026 e Strategic collaborations with Bayer and upcoming tri
Slide 25: Investor Relations
KAIROS ry PHARMA INVESTOR RELATIONS Louie Toma MANAGING DIRECTOR: CorelR NYSE American: KAPA
Kairos Pharma — Investor Presentation (September 2026) on 6ix